Publications by authors named "Young Hoon Jeong"
Aim To assess an optimal long-term antiplatelet strategy in patients at both high ischaemic and bleeding risks after percutaneous coronary intervention (PCI). Methods and results Patients both at high ischaemic and bleeding risks were eligible for inclusion. We excluded patients with any ischaemic and major bleeding complications during the mandatory period of dual antiplatelet therapy (DAPT).
View Article and Find Full Text PDFCurrent evidence indicates that dual antiplatelet therapy with aspirin plus a P2Y inhibitor is essential for the prevention of thrombotic events after percutaneous coronary interventions. However, dual antiplatelet therapy is associated with increased bleeding which may outweigh the benefits. This has set the foundations for customizing antiplatelet treatments to the individual patient.
View Article and Find Full Text PDFCalcium channel blockers (CCBs) are frequently co-administered with clopidogrel in cardiovascular disease. Although an inhibitory drug interaction exists between them, comprehensive large-scale studies for its validation are lacking. We investigated interactions between CCBs and clopidogrel using a large-scale national registry of patients who underwent percutaneous coronary intervention (PCI).
View Article and Find Full Text PDFAntithrombotic agents, including antiplatelet agents and anticoagulants, are widely used in Korea because of the increasing incidence of cardiocerebrovascular disease and the aging population. The management of patients using antithrombotic agents during endoscopic procedures is an important clinical challenge. The clinical practice guidelines for this issue, developed by the Korean Society of Gastrointestinal Endoscopy, were published in 2020.
View Article and Find Full Text PDFAdherence to lifestyle recommendations is crucial in managing hypertension, independent of medical treatment. This study aimed to evaluate the implementation of adherence to lifestyle recommendations and analyze the trends in adherence to lifestyle recommendations among patients with hypertension in Korea from 2007 to 2021 using the Korea National Health and Nutrition Examination Survey (KNHANES). The study included adults aged ≥20 years.
View Article and Find Full Text PDFArticle Synopsis
- The study examined the effects of proton pump inhibitors (PPIs) on patients who underwent percutaneous coronary intervention (PCI) while taking clopidogrel for antiplatelet therapy, particularly focusing on their clinical outcomes and PRU levels.
- Among 13,160 patients, those using PPIs had higher PRU levels but did not show a significant increase in serious cardiovascular events when compared to non-users, with primary outcomes occurring in a similar proportion.
- However, for patients carrying certain genetic variations (CYP2C19 loss-of-function alleles), PPI use was associated with an increased risk of adverse outcomes, highlighting complex interactions between medication and genetics.
The burden of cardiovascular disease in Asia from 2025 to 2050: a forecast analysis for East Asia, South Asia, South-East Asia, Central Asia, and high-income Asia Pacific regions.
Lancet Reg Health West Pac
August 2024
Article Synopsis
- A study forecasts a 91.2% increase in crude cardiovascular disease (CVD) mortality in Asia from 2025 to 2050, despite a 23.0% decrease in the age-standardized mortality rate.
- Ischaemic heart disease and stroke will remain the top causes of mortality, with Central Asia experiencing the highest mortality rates while high systolic blood pressure is identified as the leading risk factor across most of Asia.
- The research highlights the need for targeted health interventions due to the significant variations in CVD burden across different regions in Asia.
Antithrombotic agents, including antiplatelet agent and anticoagulants are widely used in Korea due to increasing incidence of cardio-cerebrovascular disease and aging population. The management of patients using antithrombotic agents during endoscopic procedures is an important clinical challenge. Clinical practice guideline regarding this issue which was developed by the Korean Society of Gastrointestinal Endoscopy was published in 2020.
View Article and Find Full Text PDFObjective: The long-term clinical effect of arterial stiffness in high-risk disease entities remains unclear. The prognostic implications of brachial-ankle pulse wave velocity (baPWV) were assessed using a real-world registry that included patients who underwent percutaneous coronary intervention (PCI).
Methods: Arterial stiffness was measured using baPWV before discharge.
Article Synopsis
- In a study of heart patients getting a special procedure called PCI, researchers looked at how two drugs, colchicine and aspirin, affected inflammation and blood clotting.
- They found that patients taking colchicine had lower levels of inflammation compared to those taking aspirin after one month.
- However, both groups showed similar levels of blood clotting, meaning colchicine helped with inflammation without making blood clots more likely.
Background And Aims: Platelet-fibrin clot strength (PFCS) is linked to major adverse cardiovascular event (MACE) risk. However, the association between PFCS and platelet reactivity and their prognostic implication remains uncertain in patients undergoing percutaneous coronary intervention (PCI).
Methods: In PCI-treated patients (n = 2512) from registry data from January 2010 to November 2018 in South Korea, PFCS using thromboelastography and platelet reactivity using VerifyNow were measured.
Background: Carriers of loss-of-function alleles have increased adverse events after percutaneous coronary intervention, but limited data are available for older patients. We aimed to evaluate the prognostic impact of genotypes on clinical outcomes in older patients after percutaneous coronary intervention.
Methods And Results: The study included 1201 older patients (aged ≥75 years) who underwent percutaneous coronary intervention and received clopidogrel-based dual antiplatelet therapy in South Korea.
Background: Debates persist regarding the optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in coronary artery disease (CAD). Recent trials have introduced a novel approach involving P2Y12 inhibitor monotherapy with ticagrelor or clopidogrel, after a short DAPT. However, the effectiveness and safety of this strategy remains to be established.
View Article and Find Full Text PDFThis study evaluated the association of atherogenic index of plasma (AIP) with platelet reactivity and clinical outcomes according to acute myocardial infarction (AMI). The composite of 3-year adverse outcomes of all-cause death, myocardial infarction, and cerebrovascular accident was evaluated in 10,735 patients after successful percutaneous coronary intervention with drug-eluting stents. AIP was defined as the base 10 logarithm of the ratio of triglyceride to high-density lipoprotein cholesterol concentration.
View Article and Find Full Text PDFArticle Synopsis
- Current guidelines suggest complete revascularization (CR) for stable patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVD), but the best timing for the procedure is still unclear.
- The OPTION-STEMI trial investigates whether immediate CR during a primary angioplasty is as effective as in-hospital staged CR, using fractional flow reserve (FFR) assessments for certain lesions.
- The trial enrolled patients with significant non-infarct-related artery lesions, aiming to measure outcomes like death and myocardial infarction one year post-randomization, with results expected in mid-2025.
Background: Although age and body mass index (BMI) significantly affect platelet reactivity units and clinical outcomes after percutaneous coronary intervention, there are limited data on the relationship between high on-treatment platelet reactivity (HPR) and clinical outcomes on age and BMI differences. Thus, we investigated the association of HPR with clinical outcomes according to age and BMI.
Methods And Results: The study analyzed 11 714 patients who underwent platelet function tests after percutaneous coronary intervention.
Antithrombotic agents, including antiplatelet agents and anticoagulants, are widely used in Korea because of the increasing incidence of cardiocerebrovascular disease and the aging population. The management of patients using antithrombotic agents during endoscopic procedures is an important clinical challenge. The clinical practice guidelines for this issue, developed by the Korean Society of Gastrointestinal Endoscopy, were published in 2020.
View Article and Find Full Text PDFArticle Synopsis
- "Long COVID" refers to ongoing symptoms from COVID-19 that last over three months, creating a significant public health challenge worldwide.
- The guidelines for diagnosis and treatment of long COVID are based on recent research and expert consensus, addressing 32 key questions related to the condition.
- Comprehensive evaluations for long COVID patients should include medical history and tests, and vaccination plus antiviral treatment during the acute phase are recommended to lower the risk of long COVID.
Background: Complex percutaneous coronary intervention (C-PCI) and high platelet reactivity (HPR) have been proposed as representative risk factors for the high ischemic phenotype. Uncertainty remains regarding the relative prognostic importance of these factors.
Objectives: This study aimed to investigate the prognostic implication of HPR according to procedural complexity.
Background: Coronary artery disease patients undergoing percutaneous coronary intervention (PCI) often exhibit reduced left ventricular ejection fraction (LVEF). However, the impact of LV dysfunction status in conjunction with platelet reactivity on clinical outcomes has not been previously investigated.
Methods: From the multicenter PTRG-DES (Platelet function and genoType-Related long-term prognosis in DES-treated patients) consortium, the patients were classified as preserved-EF (PEF: LVEF ≥ 50%) and reduced-EF (REF: LVEF< 5 0%) group by echocardiography.
Article Synopsis
- - Stent thrombosis (ST) is a serious complication after coronary artery procedures, and the link between P2Y12 reaction unit (PRU) levels and ST is still not fully understood.
- - Analysis of 11,714 patients from the PTRG-DES registry found that higher PRU and aspirin reaction unit levels are independent predictors of early stent thrombosis (EST), which occurred in 51 patients.
- - The risk of major cardiovascular events within a year was significantly greater for those who had EST (38.2%) compared to those who did not (3.9%), highlighting the importance of monitoring platelet activity after drug-eluting stent procedures.
Background: East Asians have shown different risk profiles for both thrombophilia and bleeding than Western counterparts.
Objectives: The authors sought to evaluate the effect of low-dose aspirin for primary prevention between these populations.
Methods: We searched randomized clinical trials (RCTs) for intervention with low-dose aspirin (≤100 mg once daily) in participants without symptomatic cardiovascular disease until December 31, 2021.